C Diff Drug Development

Eric Shaff, president and CEO of Seres Therapeutics, discusses the confirmatory trial findings for SER-109. Seres is filing a Biologics License Application for the recurrent C diff therapy.

Eric Schaff, president and CEO of Seres Therapeutics, discusses the confirmatory trial findings for SER-109. Seres is filing a Biologics License Application for the recurrent C diff therapy.

Essential oils of wild oregano, black pepper and garlic are candidates for adjunctive therapeutics in the treatment of CDI. Oregano oil should certainly be preferred due to the lack of selectivity of action in relation to the ribotype, the strength of the produced biofilm and/or antibiotic-susceptib …

Patients with recurrent C difficile infection receiving SER-109 experienced reduced rates of infection as early as 4 weeks following treatment.

Eric Schaff, president and CEO of Seres Therapeutics, discusses the confirmatory trial findings for SER-109. Seres is filing a Biologics License Application for the recurrent C diff therapy.

Paul Feuerstadt, MD, on the pooled analysis that compared medical history and demographics

.@PhaseGenomics received funding from the @GatesFoundation and @NIAIDFunding to develop an atlas of #phage-bacteria interactions and identify phages that can be used in therapeutic settings such as #Cdiff, #UlcerativeColitis, and #CrohnsDisease.📍 https://t.co/NZmoL9Ltdo pic.twitter.com/kWpXRwokqw— Science in Seattle (@science_seattle) June 13, 2022

Innovative efforts at the University of Virginia School of Medicine to use a harmless amoeba to protect children from dangerous infections has won critical financial support from The Hartwell …

SER-109, the investigational oral microbiome therapeutic from Seres, reduced C diff recurrence by 91.3% in at-risk populations.

DelveInsight’s “Clostridium Difficile Infection (CDI) Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Clostridium Difficile Infection (CDI), historical and forecasted epidemiology as well as the Clostridium Difficile Infection (CDI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. DelveInsight has launched a new […]

Clostridioides difficile infection (CDI) remains a significant health threat worldwide. C. difficile is an opportunistic, toxigenic pathogen that takes advantage of a disrupted gut microbiome to grow and produce signs and symptoms ranging from diarrhea to pseudomembranous colitis. Antibiotics used t …

Seres Therapeutics, Inc. announced that the company’s Phase III Ecospor IV study demonstrated a strong safety profile in addition to statistically significant positive results against C. difficile infection.

Shares of Seres Therapeutics Inc. undefined jumped 14.2% in premarket trading on Tuesday after the company shared data from a Phase 3 open-label study that...

Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection.

In ECOSPOR III, the lead therapeutic candidate incorporated itself durably and rapidly into the microbiome to prevent recurrence, the company says.

Ken Blount, PhD, chief scientific officer at Rebiotix, discusses the investigative treatment RBX2660 and its unique approach to treating Clostridioides difficile infection.

SER-109 engraftment was durable through week 24 and significantly higher than placebo at all time points for all comparisons.

Ten days after Finch Therapeutics let go 20% of its workforce, the winds have changed. | Ten days after Finch Therapeutics let go 20% of its workforce, the winds have changed. The FDA has lifted a clinical hold on the biotech’s donor-derived microbiome drug for Clostridioides difficile, clearing the way for a phase 3 study to proceed—eventually.

The US Centers for Disease Control and Prevention (CDC) lists Clostridioides difficile as an urgent bacterial threat. Yet, only two drugs, vancomycin and fidaxomicin, are approved by the FDA for the treatment of C. difficile infections as of this writing, while the global pipeline of n …

Clostridioides difficile is an opportunistic gut pathogen which causes severe colitis, leading to significant morbidity and mortality due to its toxins, TcdA and TcdB. Two intra-muscular toxoid vaccines entered Phase III trials and strongly induced toxin-neutralising antibodies systemically b …

A synthesized antibiotic derived from computer models of bacterial gene products appears to neutralize even drug-resistant bacteria. The compound, named cilagicin, works well in mice and employs a novel mechanism to attack MRSA, C. diff, and several other deadly pathogens.

RBX2660, an investigational microbiota-based live biotherapeutic for the treatment of C difficile, safely and effectively reduced recurrent C diff for 6 months.

Using neutrons, researchers at Oak Ridge National Laboratory pieced together the molecular mechanics behind a peptide’s ability to deal significant damage to

Exploring the benefits of metal Ions in phage cocktail for the treatment of methicillin-resistant Staphylococcus aureus infection

RBX2660 was shown to be safe and effective at reducing recurrence in #Cdiff #infection - great talk by Paul Feuerstadt at #DDW2022 #microbes #treatment pic.twitter.com/1bEk8bxH3S— Mindy Engevik (@MicroMindy) May 24, 2022

RBX2660, an investigational microbiota-based live biotherapeutic for the treatment of C difficile, safely and effectively reduced recurrent C diff for 6 months.

SOMERVILLE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to